BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attackHighlevel results from the Phase III THALES trial showed AstraZenecas BRILINTA ticagrelor 90 mg used twice daily and taken with aspiri...
↧